London · Delayed Price · Currency is GBP · Price in USD Sangamo Therapeutics Statistics
Total Valuation
LON:0R1D has a market cap or net worth of GBP 108.12 million. The enterprise value is 104.93 million.
| Market Cap | 108.12M |
| Enterprise Value | 104.93M |
Important Dates
The last earnings date was Thursday, November 6, 2025.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 301.71M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +28.25% |
| Shares Change (QoQ) | +18.42% |
| Owned by Insiders (%) | 1.26% |
| Owned by Institutions (%) | 18.48% |
| Float | 294.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.42 |
| PB Ratio | 23.28 |
| P/TBV Ratio | 23.28 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.31 |
| EV / Sales | 4.20 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.85 |
Financial Position
The company has a current ratio of 0.88, with a Debt / Equity ratio of 4.07.
| Current Ratio | 0.88 |
| Quick Ratio | 0.69 |
| Debt / Equity | 4.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.33 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -480.02% and return on invested capital (ROIC) is -141.24%.
| Return on Equity (ROE) | -480.02% |
| Return on Assets (ROA) | -69.61% |
| Return on Invested Capital (ROIC) | -141.24% |
| Return on Capital Employed (ROCE) | -289.02% |
| Revenue Per Employee | 133,645 |
| Profits Per Employee | -437,510 |
| Employee Count | 183 |
| Asset Turnover | 0.33 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -328,821 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -80.40% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -80.40% |
| 50-Day Moving Average | 0.60 |
| 200-Day Moving Average | 0.68 |
| Relative Strength Index (RSI) | 31.67 |
| Average Volume (20 Days) | 111,176 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, LON:0R1D had revenue of GBP 24.46 million and -80.06 million in losses. Loss per share was -0.32.
| Revenue | 24.46M |
| Gross Profit | 6.84M |
| Operating Income | -82.82M |
| Pretax Income | -81.35M |
| Net Income | -80.06M |
| EBITDA | -79.66M |
| EBIT | -82.82M |
| Loss Per Share | -0.32 |
Balance Sheet
The company has 22.03 million in cash and 18.91 million in debt, giving a net cash position of 3.12 million.
| Cash & Cash Equivalents | 22.03M |
| Total Debt | 18.91M |
| Net Cash | 3.12M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 4.64M |
| Book Value Per Share | 0.01 |
| Working Capital | -4.50M |
Cash Flow
In the last 12 months, operating cash flow was -56.66 million and capital expenditures -178,546, giving a free cash flow of -56.83 million.
| Operating Cash Flow | -56.66M |
| Capital Expenditures | -178,546 |
| Free Cash Flow | -56.83M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 27.98% |
| Operating Margin | -338.63% |
| Pretax Margin | -332.63% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LON:0R1D does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -28.25% |
| Shareholder Yield | -28.25% |
| Earnings Yield | -74.05% |
| FCF Yield | -52.57% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |